Transparency Notification Received from Tolefi SA (Article 14 1 of the Law of 2 May 2007)

By Globe Newswire10 days ago

MONT-SAINT-GUIBERT, Belgium, May 05, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA ((Euronext &amp, NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021.

Tolefi SA has notified that its 2.295.701 shares benefit from a double voting right as of May 3, 2021 and that its shareholding has crossed above the threshold of 25%. The full transparency notice is available on the Celyad website under the heading Regulated Information.

AD

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

Continue read on benzinga.com